The objective response rate (ORR) and disease control rate (DCR) of patients with HER2-mutant lung adenocarcinoma were significantly higher than those without HER2 mutations (40.6% vs 14.9%, χ2=8.464, P=0.004; 93.8% vs 68.9%, χ2=6.327, P=0.012), and the difference was statistically significant. This evidence concerns the gene ERBB2 and lung adenocarcinoma.